Steven Cohen 2seventy Bio, Inc. Transaction History

Point72 Asset Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.09 - $6.0 $3.9 Million - $7.58 Million	1,262,702 Added 360.94%	1,612,542 $8.63 Million
Q4 2023 Feb 14, 2024	SELL	$1.57 - $4.58 $2.06 Million - $6 Million	-1,310,160 Reduced 78.93%	349,840 $1.49 Million
Q3 2023 Nov 14, 2023	BUY	$3.14 - $11.2 $1.2 Million - $4.29 Million	383,048 Added 30.0%	1,660,000 $6.51 Million
Q2 2023 Aug 14, 2023	BUY	$8.45 - $12.48 $9 Million - $13.3 Million	1,065,673 Added 504.39%	1,276,952 $12.9 Million
Q1 2023 May 15, 2023	SELL	$9.21 - $14.98 $648,116 - $1.05 Million	-70,371 Reduced 24.99%	211,279 $2.16 Million
Q4 2022 Feb 14, 2023	BUY	$8.57 - $17.0 $1.06 Million - $2.09 Million	123,200 Added 77.75%	281,650 $2.64 Million
Q3 2022 Nov 14, 2022	SELL	$12.56 - $17.54 $1 Million - $1.4 Million	-79,850 Reduced 33.51%	158,450 $2.31 Million
Q2 2022 Aug 15, 2022	SELL	$10.55 - $18.81 $763,820 - $1.36 Million	-72,400 Reduced 23.3%	238,300 $3.15 Million
Q1 2022 May 16, 2022	SELL	$11.67 - $26.72 $3.22 Million - $7.37 Million	-276,007 Reduced 47.04%	310,700 $5.3 Million
Q4 2021 Feb 14, 2022	BUY	$13.77 - $42.56 $8.08 Million - $25 Million	586,707 New	586,707 $15 Million

126

45.6M

122K

19.8K

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $150M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.